DEF 14A

Company

Inhibikase Therapeutics, Inc.

Filed

November 18, 2024

Period of Report

January 3, 2025

Accession Number

0000950170-24-127941

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →